Award: Boehringer Ingelheim is Global Top Employer 2022 Award: Boehringer Ingelheim is Global Top Employer 2022 Global Top Employer 2022
Overcoming heartworm disease for homeless pets Overcoming heartworm disease for homeless pets Heartworm-free pets soar to new lives. Together with our Greater Good Charity partners, our colleagues helped bring shelter dogs to forever homes.
License to develop new fibro-inflammatory disease treatments License to develop new fibro-inflammatory disease treatments License to develop new fibro-inflammatory disease treatments
Partnership canine oncology Partnership canine oncology The collaboration will focus on identifying new molecules to target cancers in dogs. Small molecules could provide superior disease control.
World-Psoriasis-Day-IFPA-Interview World-Psoriasis-Day-IFPA-Interview Interview with the International Federation of Psoriasis Associations (IFPA)
FDA approves Jardiance treatment chronic kidney disease FDA approves Jardiance treatment chronic kidney disease U.S. FDA approves Jardiance® for treatment of adults with chronic kidney disease
2019 performance 2019 performance Global Support Program addresses COVID-19 crisis with relief fund initiatives and volunteering support, donations, and concrete research activities.
Boehringer Ingelheim Venture Fund invests precision antimicrobials Boehringer Ingelheim Venture Fund invests precision antimicrobials Boehringer Ingelheim Venture Fund invests in the development of precision antimicrobials
Pride Month and our culture of respect Pride Month and our culture of respect Watch our colleagues from the LGBTQIA+ community and allies share their views.
New African Swine Fever Manual published New African Swine Fever Manual published Boehringer Ingelheim joined forces with the leading veterinarians to fight African swine fever. The new African Swine Fever Knowledge Handbook published.
FDA-CRL-T1D FDA-CRL-T1D US FDA issues complete response letter for treatment of adults with type 1 diabetes
U.S. FDA grants priority review for spesolimab in GPP U.S. FDA grants priority review for spesolimab in GPP U.S. FDA grants priority review for spesolimab in the treatment of patients with generalized pustular psoriasis
New biomass power plant Ingelheim New biomass power plant Ingelheim Boehringer Ingelheim produces its own green energy
BI Focuses COVID-19 Clinical Research on Alteplase BI Focuses COVID-19 Clinical Research on Alteplase BI focuses its COVID-19 therapy research on the development of alteplase as a potential treatment for COVID-19 patients with severe breathing problems
Jean-Michel Boers Appointed to PhRMA Board of Directors Jean-Michel Boers Appointed to PhRMA Board of Directors Jean-Michel Boers Appointed to PhRMA Board of Directors
Boehringer expands cancer research at Vienna site Boehringer expands cancer research at Vienna site Boehringer Ingelheim expands cancer research at its Vienna site
Promising phase II results in chronic kidney disease Promising phase II results in chronic kidney disease Boehringer Ingelheim’s investigation of novel compound on top of standard of care empagliflozin shows promising results for chronic kidney disease
Introducing CIAS Introducing CIAS Schizophrenia affects 1 in 100, yet the condition can be misunderstood due to some symptoms being overlooked, such as cognitive impairment
Niha Agarwalla Niha Agarwalla My career challenge at Boehringer Ingelheim by Niha Agarwalla. Read it now!
bix_facilitates_global_partnerships bix_facilitates_global_partnerships BI X focuses on partnerships to speed up the development of digital healthcare solutions
digital_leader_award_2020 digital_leader_award_2020 Boehringer Ingelheim wins first place in the "STRATEGY" category of the Digital Leader Award